CardioPoietis LLC is a company commercializing a drug expected to reduce the damage to the heart during a heart attack by 30 to 35 percent compared to the current standard treatment. There is also promising evidence that it may provide similar protective effects for the brain during a stroke. Currently, two U.S.-issued patents for the idea and usage of this drug are owned by the company. CardioPoietis presented during the WAN Investors’ Track at the Wisconsin Early Stage Symposium on Nov. 12 in Madison.
Read the full WisBusiness story here.